|
|
楼主 |
发表于 2024-5-9 10:18:51
|
显示全部楼层
, s3 E6 X4 a0 N, i: `- d
我看了下，入选今年ASCO的中肿研究，有4项是随机、3期临床试验，2项鼻咽癌+2项肺癌，这4项应该都能发很不错的文章，其余1-2期的应该也有子刊的水平
1 m9 Q5 X$ G" ~( X! u
% |/ U' _( H9 `6 C4 m0 QIvonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.
9 w$ o5 ~8 L) d) f6 o. @Ivonescimab联合化疗治疗接受EGFR-TKI治疗进展的EGFR突变非鳞状NSCLC患者(HARMONi-A)：一项随机、双盲、多中心、III期试验' q9 p! p2 o. V" w5 u( b( H' G. ~
讲者：张力 中山大学肿瘤防治中心
) A- \; O( T4 A, P. p" z
7 {4 u1 ~3 F( r: D7 }. {5 ^: ] G* BAdjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.! U" ~1 e, y+ ~$ ~
可切除EGFR突变II-IIIA期NSCLC接受12个月或6个月的埃克替尼辅助治疗对比辅助化疗后观察：一项随机III期试验(ICTAN，GASTO1002). \8 G" a9 a' ?
讲者：王思愚 中山大学肿瘤防治中心, i2 p" g0 y4 X" N' J, @5 L, o
. H0 {( ?! C0 y. qTislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial./ \# p& C2 C4 R4 `
替雷利珠单抗对比安慰剂联合诱导化疗序贯同步放化疗，继以替雷利珠单抗或安慰剂辅助治疗局部晚期鼻咽癌：一项多中心、随机、安慰剂对照、双盲、III期试验的期中分析
1 z5 S3 d( t) c+ B& \5 g ]' U讲者：陈秋燕 中山大学肿瘤防治中心# H& n! D: T- A! }; I
- H9 t& N6 }/ t% V1 j0 A
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.1 Y, l G6 U6 O1 D& _
卡瑞利珠单抗辅助治疗高危局部晚期鼻咽癌(DIPPER)：一项多中心、开放标签、III期随机对照试验
3 c" M' Z" A" R3 H3 [讲者：刘需 中山大学肿瘤防治中心" e; o) N- D; T* T$ B0 I! i
2 c: ?: W; {! O! A. ]$ i7 m |
|
[复制链接]
发表于 2024-5-9 08:59:18
